Korro Bio, Inc. (KRRO) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
the bull case· 3
3
funds on file reporting a position in the company
n-portas of Jun 30 '26+4.73%
largest reporting managers increasing shares over the latest quarter
13fJun 30 '26108
managers reporting a position in institutional regulatory filings
13fJun 30 '26the bear case· 3
0.00%
largest reported fund weight among tracked funds
n-portJun 30 '263 of 4
recent reports where the move landed below the options implied range
earnings historyimplied vs realized3 of 23
largest reporting managers that reduced their stake in the latest quarter
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 12 '26 report. Not a forecast, not advice.
Of the 6 companies Korro Bio, Inc. moves with most closely, none share its SEC classification.
Measured against 500 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
Korro Bio, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
High 11.85 at 8:30 am ET, low 9.72 at 2:00 pm ET.
KRRO (Korro Bio, Inc.) has 0 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
tall tick = annual report · 1 on record
107 managers report a position worth $191.9M between them, and 17 of them hold 80% of it.